Synthesis and Biological Evaluation of Paclitaxel-aminoguanidine Conjugates for Suppressing Breast Cancer
Authors:
- 1 December 2023
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 20 (8) , 890-896
Abstract
Background: A combination of paclitaxel with antineoplastic agents or paclitaxel alone was used clinically for the treatment of metastatic breast cancer. However, paclitaxel has poor water solubility and limited effect on some metastatic breast cancers. Hence, novel paclitaxel derivatives are in demand. In addition, the inducible nitric oxide synthase inhibitor, and aminoguanidine has a synergistic antitumor effect with chemotherapeutics. Objective: This study aims to design and synthesize the paclitaxel-aminoguanidine conjugates. Upon cellular internalization, the novel paclitaxel-aminoguanidine conjugates could release paclitaxel and aminoguanidine with the aid of esterase and weak acids in cancer cells. Methods: Paclitaxel-aminoguanidine conjugates were synthesized using click chemistry. The biological activity of paclitaxel-aminoguanidine conjugates was evaluated by MTT assay, determination of nitric oxide, analysis of apoptosis and cell cycle, and wound healing assay. Results: Here, a novel paclitaxel-aminoguanidine conjugate was synthesized using click chemis-try. Compared with paclitaxel, the water solubility of paclitaxel-aminoguanidine conjugates increased obviously. Upon cellular internalization, the novel paclitaxel-aminoguanidine conjugates released paclitaxel and aminoguanidine to synergistically inhibit the proliferation and metastasis of breast cancer cells with the aid of esterase and weak acids in cancer cells. The results of the MTT assay showed that compared with paclitaxel or the mixture of paclitaxel and aminoguanidine, the cytotoxicity of compound 4 against 4T1 cells was enhanced. As for apoptosis induced by these compounds, the paclitaxel-aminoguanidine conjugates also had a stronger ability to induce apoptosis than paclitaxel or the mixture of paclitaxel and aminoguanidine. The results of the scratch test showed that the anti-metastatic effect of the con-jugate was the strongest among these tested compounds. Conclusion: These findings indicate that paclitaxel-aminoguanidine conjugate is a promising anticancer agent worthy of further study.Keywords
Funding Information
- Natural Science Research Foundation of the Department of Education of Anhui Province (KJ2021A1166, KJ2019A0873)
- Scientific Research Team of Anui Xinhua University (kytd202211)
- Pharmaceutical Institute of Anui Xinhua University (yjs202107)
- Innovation and Entrepreneurship training Program for College students in Anhui Province (201912216193, 201912216194)
This publication has 24 references indexed in Scilit:
- Inhibitory growth evaluation and apoptosis induction in MCF-7 cancer cells by new 5-aryl-2-butylthio-1,3,4-oxadiazole derivativesCancer Chemotherapy and Pharmacology, 2017
- Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathwaysOncotarget, 2017
- Prodrug Strategies for PaclitaxelInternational Journal of Molecular Sciences, 2016
- Design and development of oxobenzimidazoles as novel androgen receptor antagonistsMedicinal Chemistry Research, 2016
- Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool BoxMolecules, 2015
- Nitric oxide in cancer metastasisCancer Letters, 2014
- Paclitaxel Therapy Promotes Breast Cancer Metastasis in a TLR4-Dependent MannerCancer Research, 2014
- A micellar prodrug of paclitaxel conjugated to cyclotriphosphazeneBioorganic & Medicinal Chemistry Letters, 2008
- Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrinsJournal of Bioscience and Bioengineering, 2006
- The role of nitric oxide in tumour progressionNature Reviews Cancer, 2006